发明申请
- 专利标题: Compounds For Enzyme Inhibition
- 专利标题(中): 化合物用于酶抑制
-
申请号: US13341022申请日: 2011-12-30
-
公开(公告)号: US20120101025A1公开(公告)日: 2012-04-26
- 发明人: Mark S. Smyth , Guy J. Laidig , Ronald T. Borchardt , Barry A. Bunin , Craig M. Crews , John H. Musser , Kevin D. Shenk , Peggy A. Radel
- 申请人: Mark S. Smyth , Guy J. Laidig , Ronald T. Borchardt , Barry A. Bunin , Craig M. Crews , John H. Musser , Kevin D. Shenk , Peggy A. Radel
- 申请人地址: US CA South San Francisco
- 专利权人: ONYX THERAPEUTICS, INC.
- 当前专利权人: ONYX THERAPEUTICS, INC.
- 当前专利权人地址: US CA South San Francisco
- 主分类号: A61K38/06
- IPC分类号: A61K38/06 ; A61P17/06 ; A61P11/08 ; A61P11/00 ; A61P31/18 ; A61P25/28 ; A61P25/00 ; A61P9/10 ; A61P25/02 ; A61P25/16 ; A61P31/04 ; A61P33/00 ; A61P31/12 ; A61P21/00 ; A61P35/00 ; A61P27/02 ; A61P9/04 ; A61P17/00 ; A61P37/00 ; A61P37/06 ; A61P19/02 ; A61P1/00 ; A61P31/00 ; A61P13/12 ; A61P1/16 ; A61P11/06 ; A61P37/08 ; A61P1/18 ; A61P29/00
摘要:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
信息查询
IPC分类: